These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15029112)

  • 1. Improved symptoms, physical limitation, and self-efficacy after resynchronization in a patient with heart failure and a prolonged QRS duration.
    Conaway DG; Sullivan R; McCullough PA
    Rev Cardiovasc Med; 2004; 5(1):53-7. PubMed ID: 15029112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
    Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
    J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of brain natriuretic peptide to evaluate patients with heart failure treated with cardiac resynchronization].
    Hernández Madrid A; Miguelañez Díaz M; Escobar Cervantes C; Blanco Tirados B; Marín I; Bernal E; Zamora J; Cordova González FJ; Alfonso Pérez M; Limón L; González Rebollo JM; Moya Mur JL; Moro C
    Rev Esp Cardiol; 2004 Apr; 57(4):299-305. PubMed ID: 15104983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy.
    Glick A; Michowitz Y; Keren G; George J
    Isr Med Assoc J; 2006 Jun; 8(6):391-5. PubMed ID: 16833167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
    Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
    Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cardiac resynchronization therapy on disease progression in patients with congestive heart failure.
    Bonanno C; Ometto R; Pasinato S; Finocchi G; La Vecchia L; Fontanelli A
    Ital Heart J; 2004 May; 5(5):364-70. PubMed ID: 15185900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure.
    Mollema SA; Bleeker GB; van der Wall EE; Schalij MJ; Bax JJ
    Am J Cardiol; 2007 Dec; 100(11):1665-70. PubMed ID: 18036366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Brain natriuretic peptide and QRS duration as a predictor for cardiac events in patients with heart failure].
    Taniguchi T; Kawasaki T; Miyai N; Kamitani T; Kawasaki S; Sugihara H
    J Cardiol; 2006 Jun; 47(6):277-83. PubMed ID: 16800370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure?
    Turley AJ; Raja SG; Salhiyyah K; Nagarajan K
    Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1141-6. PubMed ID: 18541605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upgrade to biventricular pacing in patients with conventional pacemakers and heart failure: a double-blind, randomized crossover study.
    Höijer CJ; Meurling C; Brandt J
    Europace; 2006 Jan; 8(1):51-5. PubMed ID: 16627409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between B-type natriuretic peptide and health status in patients with heart failure.
    Luther SA; McCullough PA; Havranek EP; Rumsfeld JS; Jones PG; Heidenreich PA; Peterson ED; Rathore SS; Krumholz HM; Weintraub WS; Spertus JA; Masoudi FA;
    J Card Fail; 2005 Aug; 11(6):414-21. PubMed ID: 16105631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits of biventricular pacing in heart failure patients with narrow QRS, NYHA class II and right ventricular pacing.
    Ng K; Kedia N; Martin D; Tchou P; Natale A; Wilkoff B; Starling R; Grimm RA
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):193-8. PubMed ID: 17338715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
    Fruhwald FM; Fahrleitner-Pammer A; Berger R; Leyva F; Freemantle N; Erdmann E; Gras D; Kappenberger L; Tavazzi L; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jul; 28(13):1592-7. PubMed ID: 17298973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term hemodynamic effects of cardiac resynchronization therapy in patients with heart failure, a narrow QRS duration, and no dyssynchrony.
    Williams LK; Ellery S; Patel K; Leyva F; Bleasdale RA; Phan TT; Stegemann B; Paul V; Steendijk P; Frenneaux M
    Circulation; 2009 Oct; 120(17):1687-94. PubMed ID: 19822812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical and emotional symptom burden of patients with end-stage heart failure: what to measure, how and why.
    Opasich C; Gualco A; De Feo S; Barbieri M; Cioffi G; Giardini A; Majani G
    J Cardiovasc Med (Hagerstown); 2008 Nov; 9(11):1104-8. PubMed ID: 18852581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac resynchronization therapy and B-type natriuretic peptide in heart failure.
    Huang DJ
    Chin Med J (Engl); 2009 Mar; 122(6):608-9. PubMed ID: 19323919
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic heart failure patients with restrictive LV filling pattern have significantly less benefit from cardiac resynchronization therapy than patients with late LV filling pattern.
    Salukhe TV; Francis DP; Clague JR; Sutton R; Poole-Wilson P; Henein MY
    Int J Cardiol; 2005 Apr; 100(1):5-12. PubMed ID: 15820279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac resynchronization therapy in patients with end-stage inotrope-dependent class IV heart failure.
    Herweg B; Ilercil A; Cutro R; Dewhurst R; Krishnan S; Weston M; Barold SS
    Am J Cardiol; 2007 Jul; 100(1):90-3. PubMed ID: 17599447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QRS duration, an indirect reflection of ventricular synergy, is not altered in decompensated heart failure.
    Lindberg M; Li Z; Amsterdam EA; Srivatsa U
    Crit Pathw Cardiol; 2009 Jun; 8(2):88-90. PubMed ID: 19491575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.